Male Hypogonadism Market 2027 by Therapy, Drug Delivery, Type | The Insight Partners

Male Hypogonadism Market Forecast to 2027 - Covid-19 Impact and Global Analysis - by Therapy (Testosterone Replacement Therapy, Gonadotropin and Gonadotropin-Releasing Hormones Therapy); Drug Delivery (Topical Gels, Injectable, Transdermal Patches, Others); Type (Klinefelter's Syndrome, Kallmann Syndrome, Pituitary Disorders, Others)

Report Code: TIPRE00008244 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming
Covid
MARKET INTRODUCTION

Male hypogonadism is a failure of the testes that produce the male test hormone testosterone, sperm, or both. It can be due to a testicular disorder or the result of a disease process involving the hypothalamus and pituitary gland.

MARKET DYNAMICS

The male hypogonadism market is anticipated to grow owing to increasing case of testosterone deficiency among men. However, high side effects is one of the major restraints for the market growth. Moreover, rising geriatric population all across the world coupled with rising cases of obesity and rheumatoid arthritis are expected to benefit the growth of the market in the forecast period.

MARKET SCOPE

The "Male Hypogonadism Market Analysis to 2027" is a specialized and in-depth study of the pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of in male hypogonadism market with detailed market segmentation by therapy, drug delivery, type and geography. The male hypogonadism market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading in male hypogonadism market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The male hypogonadism market is segmented on the basis of therapy, drug delivery and type. Based on therapy the market is segmented as testosterone replacement therapy and gonadotropin and gonadotropin-releasing hormones therapy. Further on the basis of gonadotropin and gonadotropin-releasing hormones therapy the market is segmented as luteinizing hormone (LH), follicle-stimulating hormone (FSH), human chorionic gonadotropin (hCG) and gonadotropin-releasing hormone (GnRH). On the basis of drug delivery the market is categorized as topical gels, injectable, transdermal patches and others. On the basis of type the market is categorized as klinefelter's syndrome, kallmann syndrome, pituitary disorders and others.



Get more information on this report :

REGIONAL FRAMEWORK


The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the in male hypogonadism market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The male hypogonadism market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting male hypogonadism market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the male hypogonadism market in these regions.



Get more information on this report :

MARKET PLAYERS


The report covers key developments in the in male hypogonadism market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from in male hypogonadism market are anticipated to have lucrative growth opportunities in the future with the rising demand for in male hypogonadism market in the global market. Below mentioned is the list of few companies engaged in the male hypogonadism market.

The report also includes the profiles of key in male hypogonadism market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.

  •  AbbVie Inc.
  •  Allergan plc
  •  Astrazeneca plc
  •  Bayer AG
  •  Eli Lilly and Company Ltd.
  •  Endo International plc.
  •  Finox Biotech,
  •  Laboratoires Genevrier
  •  Merck & Co., Inc.
  •  Teva Pharmaceutical Industries Ltd.

The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.


Get more information on this report :

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Male Hypogonadism Market - By Therapy
1.3.2 Male Hypogonadism Market - By Drug Delivery
1.3.3 Male Hypogonadism Market - By Type
1.3.4 Male Hypogonadism Market - By Region
1.3.4.1 By Country

2. KEY TAKEAWAYS

3. RESEARCH METHODOLOGY

4. MALE HYPOGONADISM MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS

5. MALE HYPOGONADISM MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS, RESTRAINTS & EXPECTED INFLUENCE OF COVID-19 PANDEMIC

6. MALE HYPOGONADISM MARKET - GLOBAL MARKET ANALYSIS
6.1. MALE HYPOGONADISM - GLOBAL MARKET OVERVIEW
6.2. MALE HYPOGONADISM - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE

7. MALE HYPOGONADISM MARKET - REVENUE AND FORECASTS TO 2027 - THERAPY
7.1. OVERVIEW
7.2. THERAPY MARKET FORECASTS AND ANALYSIS
7.3. TESTOSTERONE REPLACEMENT THERAPY
7.3.1. Overview
7.3.2. Testosterone Replacement Therapy Market Forecast and Analysis
7.4. GONADOTROPIN AND GONADOTROPIN-RELEASING HORMONES THERAPY
7.4.1. Overview
7.4.2. Gonadotropin and Gonadotropin-Releasing Hormones Therapy Market Forecast and Analysis
7.4.3. Luteinizing Hormone (LH) Market
7.4.3.1. Overview
7.4.3.2. Luteinizing Hormone (LH) Market Forecast and Analysis
7.4.4. Follicle-Stimulating Hormone (FSH) Market
7.4.4.1. Overview
7.4.4.2. Follicle-Stimulating Hormone (FSH) Market Forecast and Analysis
7.4.5. Human Chorionic Gonadotropin (hCG) Market
7.4.5.1. Overview
7.4.5.2. Human Chorionic Gonadotropin (hCG) Market Forecast and Analysis
7.4.6. Gonadotropin-Releasing Hormone (GnRH) Market
7.4.6.1. Overview
7.4.6.2. Gonadotropin-Releasing Hormone (GnRH) Market Forecast and Analysis

8. MALE HYPOGONADISM MARKET - REVENUE AND FORECASTS TO 2027 - DRUG DELIVERY
8.1. OVERVIEW
8.2. DRUG DELIVERY MARKET FORECASTS AND ANALYSIS
8.3. TOPICAL GELS
8.3.1. Overview
8.3.2. Topical Gels Market Forecast and Analysis
8.4. INJECTABLE
8.4.1. Overview
8.4.2. Injectable Market Forecast and Analysis
8.5. TRANSDERMAL PATCHES
8.5.1. Overview
8.5.2. Transdermal Patches Market Forecast and Analysis
8.6. OTHERS
8.6.1. Overview
8.6.2. Others Market Forecast and Analysis

9. MALE HYPOGONADISM MARKET - REVENUE AND FORECASTS TO 2027 - TYPE
9.1. OVERVIEW
9.2. TYPE MARKET FORECASTS AND ANALYSIS
9.3. KLINEFELTER'S SYNDROME
9.3.1. Overview
9.3.2. Klinefelter's Syndrome Market Forecast and Analysis
9.4. KALLMANN SYNDROME
9.4.1. Overview
9.4.2. Kallmann Syndrome Market Forecast and Analysis
9.5. PITUITARY DISORDERS
9.5.1. Overview
9.5.2. Pituitary Disorders Market Forecast and Analysis
9.6. OTHERS
9.6.1. Overview
9.6.2. Others Market Forecast and Analysis

10. MALE HYPOGONADISM MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Male Hypogonadism Market Overview
10.1.2 North America Male Hypogonadism Market Forecasts and Analysis
10.1.3 North America Male Hypogonadism Market Forecasts and Analysis - By Therapy
10.1.4 North America Male Hypogonadism Market Forecasts and Analysis - By Drug Delivery
10.1.5 North America Male Hypogonadism Market Forecasts and Analysis - By Type
10.1.6 North America Male Hypogonadism Market Forecasts and Analysis - By Countries
10.1.6.1 United States Male Hypogonadism Market
10.1.6.1.1 United States Male Hypogonadism Market by Therapy
10.1.6.1.2 United States Male Hypogonadism Market by Drug Delivery
10.1.6.1.3 United States Male Hypogonadism Market by Type
10.1.6.2 Canada Male Hypogonadism Market
10.1.6.2.1 Canada Male Hypogonadism Market by Therapy
10.1.6.2.2 Canada Male Hypogonadism Market by Drug Delivery
10.1.6.2.3 Canada Male Hypogonadism Market by Type
10.1.6.3 Mexico Male Hypogonadism Market
10.1.6.3.1 Mexico Male Hypogonadism Market by Therapy
10.1.6.3.2 Mexico Male Hypogonadism Market by Drug Delivery
10.1.6.3.3 Mexico Male Hypogonadism Market by Type
10.2. EUROPE
10.2.1 Europe Male Hypogonadism Market Overview
10.2.2 Europe Male Hypogonadism Market Forecasts and Analysis
10.2.3 Europe Male Hypogonadism Market Forecasts and Analysis - By Therapy
10.2.4 Europe Male Hypogonadism Market Forecasts and Analysis - By Drug Delivery
10.2.5 Europe Male Hypogonadism Market Forecasts and Analysis - By Type
10.2.6 Europe Male Hypogonadism Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Male Hypogonadism Market
10.2.6.1.1 Germany Male Hypogonadism Market by Therapy
10.2.6.1.2 Germany Male Hypogonadism Market by Drug Delivery
10.2.6.1.3 Germany Male Hypogonadism Market by Type
10.2.6.2 France Male Hypogonadism Market
10.2.6.2.1 France Male Hypogonadism Market by Therapy
10.2.6.2.2 France Male Hypogonadism Market by Drug Delivery
10.2.6.2.3 France Male Hypogonadism Market by Type
10.2.6.3 Italy Male Hypogonadism Market
10.2.6.3.1 Italy Male Hypogonadism Market by Therapy
10.2.6.3.2 Italy Male Hypogonadism Market by Drug Delivery
10.2.6.3.3 Italy Male Hypogonadism Market by Type
10.2.6.4 Spain Male Hypogonadism Market
10.2.6.4.1 Spain Male Hypogonadism Market by Therapy
10.2.6.4.2 Spain Male Hypogonadism Market by Drug Delivery
10.2.6.4.3 Spain Male Hypogonadism Market by Type
10.2.6.5 United Kingdom Male Hypogonadism Market
10.2.6.5.1 United Kingdom Male Hypogonadism Market by Therapy
10.2.6.5.2 United Kingdom Male Hypogonadism Market by Drug Delivery
10.2.6.5.3 United Kingdom Male Hypogonadism Market by Type
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Male Hypogonadism Market Overview
10.3.2 Asia-Pacific Male Hypogonadism Market Forecasts and Analysis
10.3.3 Asia-Pacific Male Hypogonadism Market Forecasts and Analysis - By Therapy
10.3.4 Asia-Pacific Male Hypogonadism Market Forecasts and Analysis - By Drug Delivery
10.3.5 Asia-Pacific Male Hypogonadism Market Forecasts and Analysis - By Type
10.3.6 Asia-Pacific Male Hypogonadism Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Male Hypogonadism Market
10.3.6.1.1 Australia Male Hypogonadism Market by Therapy
10.3.6.1.2 Australia Male Hypogonadism Market by Drug Delivery
10.3.6.1.3 Australia Male Hypogonadism Market by Type
10.3.6.2 China Male Hypogonadism Market
10.3.6.2.1 China Male Hypogonadism Market by Therapy
10.3.6.2.2 China Male Hypogonadism Market by Drug Delivery
10.3.6.2.3 China Male Hypogonadism Market by Type
10.3.6.3 India Male Hypogonadism Market
10.3.6.3.1 India Male Hypogonadism Market by Therapy
10.3.6.3.2 India Male Hypogonadism Market by Drug Delivery
10.3.6.3.3 India Male Hypogonadism Market by Type
10.3.6.4 Japan Male Hypogonadism Market
10.3.6.4.1 Japan Male Hypogonadism Market by Therapy
10.3.6.4.2 Japan Male Hypogonadism Market by Drug Delivery
10.3.6.4.3 Japan Male Hypogonadism Market by Type
10.3.6.5 South Korea Male Hypogonadism Market
10.3.6.5.1 South Korea Male Hypogonadism Market by Therapy
10.3.6.5.2 South Korea Male Hypogonadism Market by Drug Delivery
10.3.6.5.3 South Korea Male Hypogonadism Market by Type
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Male Hypogonadism Market Overview
10.4.2 Middle East and Africa Male Hypogonadism Market Forecasts and Analysis
10.4.3 Middle East and Africa Male Hypogonadism Market Forecasts and Analysis - By Therapy
10.4.4 Middle East and Africa Male Hypogonadism Market Forecasts and Analysis - By Drug Delivery
10.4.5 Middle East and Africa Male Hypogonadism Market Forecasts and Analysis - By Type
10.4.6 Middle East and Africa Male Hypogonadism Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Male Hypogonadism Market
10.4.6.1.1 South Africa Male Hypogonadism Market by Therapy
10.4.6.1.2 South Africa Male Hypogonadism Market by Drug Delivery
10.4.6.1.3 South Africa Male Hypogonadism Market by Type
10.4.6.2 Saudi Arabia Male Hypogonadism Market
10.4.6.2.1 Saudi Arabia Male Hypogonadism Market by Therapy
10.4.6.2.2 Saudi Arabia Male Hypogonadism Market by Drug Delivery
10.4.6.2.3 Saudi Arabia Male Hypogonadism Market by Type
10.4.6.3 U.A.E Male Hypogonadism Market
10.4.6.3.1 U.A.E Male Hypogonadism Market by Therapy
10.4.6.3.2 U.A.E Male Hypogonadism Market by Drug Delivery
10.4.6.3.3 U.A.E Male Hypogonadism Market by Type
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Male Hypogonadism Market Overview
10.5.2 South and Central America Male Hypogonadism Market Forecasts and Analysis
10.5.3 South and Central America Male Hypogonadism Market Forecasts and Analysis - By Therapy
10.5.4 South and Central America Male Hypogonadism Market Forecasts and Analysis - By Drug Delivery
10.5.5 South and Central America Male Hypogonadism Market Forecasts and Analysis - By Type
10.5.6 South and Central America Male Hypogonadism Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Male Hypogonadism Market
10.5.6.1.1 Brazil Male Hypogonadism Market by Therapy
10.5.6.1.2 Brazil Male Hypogonadism Market by Drug Delivery
10.5.6.1.3 Brazil Male Hypogonadism Market by Type
10.5.6.2 Argentina Male Hypogonadism Market
10.5.6.2.1 Argentina Male Hypogonadism Market by Therapy
10.5.6.2.2 Argentina Male Hypogonadism Market by Drug Delivery
10.5.6.2.3 Argentina Male Hypogonadism Market by Type

11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS

12. MALE HYPOGONADISM MARKET, KEY COMPANY PROFILES
12.1. ABBVIE INC.
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. ALLERGAN PLC
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. ASTRAZENECA PLC
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. BAYER AG
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. ELI LILLY AND COMPANY LTD.
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. ENDO INTERNATIONAL PLC.
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. FINOX BIOTECH
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. LABORATOIRES GENEVRIER
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. MERCK AND CO., INC.
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. TEVA PHARMACEUTICAL INDUSTRIES LTD.
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments

13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
The List of Companies

1. AbbVie Inc.
2. Allergan plc
3. Astrazeneca plc
4. Bayer AG
5. Eli Lilly and Company Ltd.
6. Endo International plc.
7. Finox Biotech,
8. Laboratoires Genevrier
9. Merck & Co., Inc.
10. Teva Pharmaceutical Industries Ltd.
TIPRE00008244
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing

Free

20%

customization on Pre-Booking